Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T22:13:24.519Z.
Calculation as of: 2026-10-06T22:13:24.519Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 717d9e1ca299c0a9e32b76938e5c8cfcb507e231e4f72cb05b36dcb8f57dd66d
PE RATIO
N/A
Market Cap
$5.82M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | $6.11M | N/A | N/A | N/A | N/A |
| Femasys Inc. (FEMY)vs › | $6.28M | N/A | N/A | N/A | N/A |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $5.92M | N/A | N/A | N/A | N/A |
| Sonoma Pharmaceuticals, Inc. (SNOA)vs › | $5.89M | N/A | 5.41 | 8.45 | 9.86 |
| Lucyd, Inc (LUCY)vs › | $5.83M | N/A | N/A | N/A | N/A |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.82M | N/A | N/A | N/A | N/A |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.73M | 0.00 | 0.02 | 0.02 | 0.02 |
| enVVeno Medical Corporation (NVNO)vs › | $5.70M | N/A | N/A | N/A | N/A |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.58M | N/A | 47.75 | 83.50 | 106.23 |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.63M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$3.76
Forward EPS (Est.)
$-0.23
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
